SLC2A1 and obstructive sleep apnea syndrome: Inhibition of SLC2A1 and cellular glucose transport has been achieved by a number of pharmaceuticals, however, as with the MMP3 inhibitors, these have yet to be utilized in OSA trials in either people or dogs (102–105).